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Background: Pathogens that establish chronic infection elicit immune responses with suppressive cytokines
dominating over pro-inflammatory cytokines. Chronic hepatitis C virus (HCV) infection, human immunodeficiency
virus (HIV) infection and simian immunodeficiency virus (SIV) infection are associated with high levels of antiviral
antibodies expressing a common idiotype specifically recognized by the 1F7 monoclonal antibody (mAb). The 1F7
mAb is a murine IgMκ antibody raised against immunoglobulin pooled from the plasma of multiple HIV-infected
individuals. In this study, we investigated direct effects of the 1F7 mAb itself on peripheral blood mononuclear cells
(PBMC).
Methods: Isolated monocytes or PBMC from healthy controls were incubated with the 1F7 mAb or IgMκ mAb
control. Cytokine production was measured in cell culture supernatants by ELISA and cells producing interleukin-10
(IL-10) were identified by subset depletion and intracellular flow cytometry. Endotoxin tolerance was assessed by
exposing monocytes to lipopolysaccharide (LPS) following 1F7 mAb or IgMκ mAb control pre-treatment and
comparing tumor necrosis factor (TNF)-α levels in cell culture supernatants.
Results: The 1F7 mAb stimulated monocytes and CD36+ lymphocytes to produce IL-10 in a time and dose-
dependent manner. Treatment of monocytes with 1F7 mAb also reduced their subsequent responsiveness to LPS
stimulation.
Conclusions: Induction of antibodies expressing the 1F7 idiotype by chronic pathogens may facilitate IL-10
production and progression to chronic infection. Direct effects of IL-10 from human monocytes stimulated by 1F7-like
antibodies, followed by monocyte transition to an alternatively activated phenotype illustrated by endotoxin tolerance,
are two complementary features favouring a tolerogenic or non-responsive immunological environment.
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Immunoglobulins contain unique primary sequences that
are created by Ig gene rearrangement and further diversi-
fied by somatic hypermutation. The integrated compos-
ition of immunogenic epitopes within the variable (V)
region of a given immunoglobulin (Ig) molecule is desig-
nated as its “idiotype” (Id). Anti-idiotypic antibodies react-
ive against determinants within the V regions of other
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of components within the V region. Public or common
idiotypes not associated with shared germ-line sequences
arise through convergent selection processes. Antibodies
with common idiotypes, but different antigenic specificity,
usually emerge within a setting of chronic immune activa-
tion. In some cases, their selection may reflect adaptive
exploitation of locally and systemically distributed idio-
typic interactions by chronic pathogens [1,2]. The anti-
idiotypic mAb 1F7 was raised in BALB/c mice injected
with immunoglobulin pooled from multiple human im-
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chain variable (VH) gene or gene family and occurs on hu-
man antibodies against (HIV) and hepatitis C virus (HCV)
and on macaque antibodies against simian immunodefi-
ciency virus (SIV) [4-7]. The 1F7 anti-idiotypic mAb re-
acts with human antibodies against HIV Env, Gag and Pol
proteins, human antibodies against different HCV pro-
teins and macaque antibodies against different SIV pro-
teins [4-8]. This broad distribution of the 1F7-defined
idiotope on parallel sets of antibodies against different
chronic pathogens positions it at a common idiotypic con-
vergence point connected to chronic infection or immune
activation.
An association between the level of antibodies express-
ing the 1F7 Id and outcome of infection was recently
shown in hepatitis C infection. The level of antibodies
reacting with the anti-idiotypic mAb 1F7 is significantly
higher in persons with chronic hepatitis C infection than
in either healthy donors or in persons who spontan-
eously cleared HCV [9]. The 1F7 Id is also more com-
mon on the Ig B cell receptors of CD5+ B1 B cells than
on the Ig B cell receptors of CD5- B cells. Since B1 B
cells are a source of interleukin-10 (IL-10), we specu-
lated that interactions between HCV proteins and B1
B cells that drive production of 1F7 Id-expressing
anti-HCV antibodies might also stimulate IL-10 pro-
duction by B1 B cells and monocytes during HCV in-
fection [10,11].
In acute HCV infection, production of pro-inflammatory
TH1-type cytokines by T cells in response to viral antigens
correlates with self-limited infection, while production of
TH2-type cytokines heralds chronic infection [12,13]. Simi-
larly, chronic HCV infection is marked by elevated TH2-
type and reduced TH1-type cytokine responses [14,15].
Peripheral TH1-type cytokines rise in parallel with viro-
logical responses to interferon-alpha (IFN-α) therapy
[16,17], while TH2-type cytokines fall together with viral
load [18,19]. The amount of IL-10 induced during acute in-
fection is a critical determinant of progression to chronic
infection versus viral clearance in certain animal model
systems and induction of IL-10 by HCV proteins has been
demonstrated in several in vitro studies [20,21]. Subjects
with untreated chronic HCV infection have elevated serum
levels of IL-10 and disease association studies of IL-10 pro-
moter polymorphisms indicate that IL-10 levels are im-
portant in both susceptibility to infection and resistance to
inflammatory disease [22].
Here we studied effects of the anti-idiotypic mAb 1F7
on IL-10 production by normal human peripheral blood
monocytes and CD36+ lymphocytes. We previously
showed that CD36+ lymphocytes (CD14-negative non-T,
non-B non-NK cells with lymphocyte forward and side
scatter characteristics by flow cytometry) constitutively
produce IL-10 and potentially influence homeostaticinnate immune suppression [23]. We also studied the in-
fluence of 1F7 mAb on IL-10 and tumor necrosis
factor-α (TNF-α) production by isolated monocytes acti-
vated by toll-like receptor 4 (TLR4) and nuclear
oligomerization domain (NOD)-like (agonists), and the
influence of 1F7 mAb on monocyte endotoxin tolerance.
Methods
Influence of 1F7 mAb on IL-10 production by peripheral
blood mononuclear cells (PBMC)
The 1F7 mAb was produced as murine hybridoma cul-
ture supernatant with IgM concentration measured by
ELISA [7]. Peripheral blood samples were obtained from
10 healthy donors (4 male and 6 female). Approval for
this study was obtained from the Ethics Committee of
Yerevan State Medical University and informed consent
was obtained from all donors. Peripheral blood mono-
nuclear cells (PBMC) were collected by histopaque-1077
(Sigma-Aldrich) gradient centrifugation of whole blood
and resuspended in RPMI-1640 medium containing 10%
fetal calf serum (FCS), 5 mM HEPES, 2 mM L-glutamine,
1 mM sodium pyruvate, 100 U penicillin, and 100 μg
streptomycin/ml (all from Invitrogen). 2.5 × 106 PBMC
were treated with 0.48-1.92 μg/ml mAb 1F7 by two-fold
dilution of 1F7 hybridoma supernatant or with an IgMκ
mAb control (eBioscience) at equivalent IgM concentra-
tions. The endotoxin content in 1F7 hybridoma super-
natant or IgMκ control was determined by Limulus
Amebocyte Lysate assay (Pyrogent, Lonza), with detection
limit 0.03 EU/ml, as per the manufacturer’s recommenda-
tions. Cells were incubated for 24, 48 and 72 h with 1F7
mAb or IgMκ control at 37°C with 5% CO2. After incuba-
tion, cells were pelleted by centrifugation and the superna-
tants collected and stored at −80°C until cytokines were
measured. The amount of IL-10 in supernatants was
determined as per the manufacturer’s instructions by
ELISA using the human IL-10 Ready-SET-Go test kit
(eBioscience) with a detection limit of 2 pg/ml.
Influence of 1F7 mAb on IL-10 production by purified
monocytes
Peripheral blood monocytes were isolated by adherence
of isolated PBMCs to 25 cm2 plastic flasks for 45 min at
37°C in 6% CO2 [24]. Adherent monocytes were washed
three times with endotoxin-free PBS and cultured at 5 × 105
cells/ml in complete medium. Lipopolysaccharide (LPS)
from E. coli 026:B6 at 100 ng/ml or 2.5 μg/ml peptidoglycan
(PGN), a NOD1 and NOD2 ligand, from E. coli 0111:B4
(both from Invivogen) were included in the culture media
from day 0 to day 3. Cell free supernatants collected at days
1 and 3 were stored at −80°C until IL-10 was measured.
Monocytes were depleted from PBMC using EasySepW hu-
man CD14 magnetic nanoparticles (Stemcell) according to
the manufacturer’s instructions. The purity of positively
Figure 1 Time and dose-dependent effects of 1F7 mAb on
IL-10 production by PBMC in vitro. PBMC from 10 individuals
were incubated with 0.48-1.92 μg/ml 1F7 mAb or IgMκ control mAb
for 18 h (a) or with 1.92 μg/ml mAb 1F7 or control for 24, 48 and 72 h
(b). The IL-10 concentration in cell free supernatants was then
measured by ELISA. Data shown represent mean values ± SE.
Mean IL-10 levels significantly different between 1F7 mAb-treated and
IgMκ mAb control-treated cell supernatants are noted (*p < 0.05).
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fluorescein isothiocyanate (FITC)-conjugated anti-CD14
(eBioscience, clone 61D3, IgG1κ) and flow cytometry,
ranged from 97.5-98.3%.
Intracellular and cell surface staining of monocytes and
lymphocytes
After PBMC incubation with the 1F7 mAb, 5 × 105 cells
were surface stained with either 0.3 μg (FITC)-conjugated
anti-CD36 (Serotec, clone SMO, IgM), anti-CD14-FITC or
isotype-matched controls for 30 min at room temperature
and fixed in 1% paraformaldehyde (Becton Dickinson).
Stained cells were incubated with 1% FACS permeabilizing
solution (Becton Dickinson), followed by phycoerythrin
(PE)-conjugated anti-human IL-10 or IL-4 (eBioscience,
clones JES3-9D7, IgG1κ and 8D4-8, IgG1κ respectively) or
isotype-matched controls and 5000 gated events were
analysed on a FACSCalibur™ instrument with CellQuest
software (Becton Dickinson). Instrument set up and colour
compensation was done using BD Calibrite™ beads and
FACSComp software. Apoptosis was monitored by meas-
uring the proportion of Annexin V-positive, PI-negative
cells using PI/Annexin V kits (BD PharMingen) [25].
Assessment of endotoxin tolerance
Endotoxin tolerance was monitored by measuring pro-
duction of TNF-α and IL-10 by monocytes in response
to LPS after preincubation with LPS or mAb 1F7 [26].
Isolated monocytes at 5 × 105 cells/ml were cultured for
18 h with 100 ng/ml LPS, 1.92 μg/ml mAb 1F7 or in
plain medium. After 18 h of culture, the monocytes were
washed three times with endotoxin-free PBS, and cul-
tured for an additional 4 h with 1 μg/ml LPS. Incubation
of monocytes with 100 ng/ml LPS, followed by rechallenge
with 1 μg/ml LPS is a standard method for assessing endo-
toxin tolerance [25,26]. At the end of the culture period,
cell-free supernatants were collected and endotoxin toler-
ance assessed by measuring human TNF-α and IL-10 with
Ready-SET-Go test kits (eBioscience) according the manu-
facturer’s instructions.
Statistical analysis
Data from independent experiments were used to calcu-
late mean values ± SE and differences were tested for stat-
istical significance (p ≤ 0.05) by Student’s paired t test.
ANOVA for repeated measures was used for analysis of
mAb 1F7 action on endotoxin tolerance induction and
cytokine production.
Results
The 1F7 mAb induces IL-10 production by PBMC in vitro
in a dose- and time-dependent manner
We first tested whether 1F7 mAb stimulated IL-10 pro-
duction by normal human PBMC in vitro. Freshly isolatedPBMC from 10 healthy donors were incubated individu-
ally for 18 h with 0.48, 0.96, 1.44 and 1.92 μg/ml 1F7
mAb, after which IL-10 was measured in culture superna-
tants. The starting concentration of IgM mAb in the hy-
bridoma supernatant was 1.92 μg/ml, therefore, dose
response was titrated from this level. We found that 1F7
mAb at 0.96, 1.44 and 1.92 μg/ml induced significant
(p = 0.01) IL-10 production in PBMC with responses
increasing in a dose-dependent manner (Figure 1a).
The timing of 1F7 mAb stimulation of IL-10 produc-
tion was studied at 1.92 μg/ml 1F7 mAb because this
concentration induced the most IL-10 secretion. 1F7
mAb-treated cells were incubated for 24, 48 and 72 h,
after which the IL-10 concentration in culture superna-
tants was measured. These time course studies (Figure 1b)
showed maximal IL-10 concentration at 24 h (62.7 ±
37.4 pg/ml), with a gradual decrease at 48 h (43.1 ±
17.9 pg/ml) and 72 h (27.1 ± 7.5 pg/ml) (p = 0.03). To test
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reflected effects of 1F7 mAb on cell survival, we assessed
apoptotic and necrotic cell death by flow cytomtery. The
results indicate that 1F7 mAb does not cause apoptotic
(Figure 2a) or necrotic (Figure 2b) cell death. Thus, secre-
tion of IL-10 by PBMC dramatically increases shortly after
treatment with 1F7 mAb, but then decreases as incubation
extends past 24 h.
1F7 mAb induces IL-10 production by CD14+ monocytes
and CD36+ lymphocytes
Next, we studied which PBMC subsets produce IL-10 in
response to 1F7 mAb. Freshly isolated PBMC from the
same 10 healthy donors were incubated with 0.48, 0.96,
1.44 and 1.92 μg/ml 1F7 mAb for 18 h and then surface
stained for CD14 and CD36, permeabilized, stained for
intracellular IL-10 and analyzed by flow cytometry
(Figure 3a). We found that in a dose-dependent manner,
1F7 mAb significantly increased the percentage of CD36+
lymphocytes (p = 0.02) and CD14+ monocytes (p = 0.03)
producing IL-10 (Figure 3b, c). To determine the major
source of IL-10 production in response to 1F7 mAb, weFigure 2 Effect of 1F7 mAb on PBMC apoptosis and necrosis.
PBMC were incubated with 1.92 μg/ml 1F7 mAb or IgMκ mAb
control for 72 h and analyzed by flow cytometry for Annexin V+,
propidium iodide (PI)- apoptotic cells (a) or PI+ necrotic cells (b).
Data shown in (a) represent mean values ± SE, n = 10. The shaded
area of a representative flow cytometry plot (b) corresponds to IgMκ
control mAb-treated cells (13.9% PI+) and the non-shaded area
corresponds to 1F7 mAb-treated cells (12.0% PI+).next compared production of IL-10 by CD14+ monocyte-
depleted and intact PBMC from 5 of the 10 healthy do-
nors. CD14+ cells were depleted using magnetic beads and
the remaining cells incubated with 1.92 μg/ml 1F7 mAb
or IgM control for 24 h, after which the IL-10 concentra-
tion in culture supernatants was measured. As shown in
Figure 3d, intact PBMC from the 5 selected healthy do-
nors incubated with 1F7 mAb produced similar amounts
of IL-10 (75.6 ± 30.4 pg/ml) to the amounts previously
produced by the 1F7 mAb stimulated PBMC of all 10
healthy donors (62.7 ± 37.4 pg/ml, Figure 1). Depletion of
CD14+ monocytes dramatically decreased IL-10 produc-
tion (Figure 3d). However, the 1F7 mAb still induced
significantly more IL-10 production by CD14+
monocyte-depleted PBMC than was induced by the
IgMκ mAb control (12.2 ± 4.8 pg/ml versus 1.99 ±
0.98 pg/ml, p = 0.02, Figure 3d).
Time-dependent 1F7 mAb stimulation of cytokine
production by PBMC subsets
Next, we studied the time-dependent action of 1F7 mAb
on IL-4 and IL-10 production by normal human mono-
cytes and lymphocytes. Freshly isolated PBMC were in-
cubated with 1.92 μg/ml 1F7 mAb or IgMκ control mAb
for 24, 48 and 72 h and the percentage of monocytes
and CD36+ lymphocytes producing IL-4 or IL-10 ana-
lyzed by flow cytometry. Similar to the time course stud-
ies carried out with PBMC (Figure 1b), 1F7 mAb
significantly increased the percentage of IL-10 producing
monocytes at 24 h (p = 0 .001), with a gradual decrease
at 48 h and 72 h (Figure 4a). In contrast, 1F7 mAb signifi-
cantly increased the percentage of IL-10 producing CD36+
lymphocytes at both 24 h (p = 0.005) and 72 h (p = 0.002).
The temporal pattern of 1F7 mAb action on IL-4 produc-
tion by CD14+ monocytes was similar to its action on
IL-10 production with a peak at 24 hours and gradual
decrease at 48 and 72 hours (Figure 4b). In contrast to
1F7 mAb’s action on IL-10 production by both mono-
cytes and lymphocytes, we saw no statistically signifi-
cant differences in IL-4 production between 1F7 mAb and
IgMκ control mAb treated cells over the 24–72 h incuba-
tion period (Figure 4a, b). Thus, we conclude that 1F7
mAb selectively induces short-term production of IL-10
by monocytes, which begins to decline after 24 hours.
1F7 mAb enhances TLR and NOD agonist-induced IL-10
production by monocytes
Recognition of pathogen-associated molecular patterns by
TLRs and NOD proteins is an important initial step in
mounting an immune response against bacteria and some
viruses. Therefore, we investigated how 1F7 mAb influenced
production of IL-10 by isolated monocytes treated with TLR
and NOD agonists. TLR agonist LPS and NOD agonist
PGN were added to isolated monocytes together with 1F7
Figure 3 Identification of PBMC subsets producing IL-10 in response to IF7 mAb. PBMC from 10 healthy donors were surface stained with
anti-CD36 or anti-CD14, fixed, permeabilized and incubated with anti-human IL-10 or matched isotype control. CD36+ lymphocytes and CD14+
monocytes were analyzed for intracellular IL-10 as shown (a). Bar graphs show mean values ± SE (b-c). Significant differences between
stimulation with mAb 1F7 and the IgMκ control mAb control are indicated (*p < 0.05). For 5 individuals, CD14+ monocytes were depleted and
the remaining cells incubated with 1.92 μg/ml 1F7 mAb or IgMκ control mAb for 24 h, after which IL-10 in culture supernatants was measured
(d). The mean IL-10 concentration in supernatant was significantly different between 1F7 mAb-treated, monocyte-depleted PBMC and intact
PBMC (*p < 0.05) and between 1F7 mAb and IgMκ control mAb-treated monocyte-depleted PBMC (#p < 0.02).
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IL-10 production was measured in culture supernatants
(Figure 5). We found that 1F7 mAb significantly increased
IL-10 production by untreated (NT) monocytes and aug-
mented IL-10 production by LPS- and PGN-stimulated
monocytes (p < 0.05). These results were somewhat unex-
pected as it was shown above that 1F7 mAb dramatically
increases production of IL-10 by monocytes at 24 h, but
then the concentration of IL-10 decreases at 48 and 72 h.
1F7 mAb induces monocyte endotoxin tolerance
To determine whether 1F7 mAb-induced production of
IL-10 is associated with anti-inflammatory (alternative)
activation of monocytes, we next studied LPS toleranceinduction in vitro. Monocytes were pretreated with LPS
at 100 ng/ml or 1F7 mAb at 1.92 μg/ml for 18 h, after
which the cells were washed with LPS-free PBS and
restimulated with LPS or 1F7 for another 4 h. Produc-
tion of TNF-α and IL-10 was subsequently measured in
cell culture supernatants. We found that at 18 h incuba-
tion, LPS, but not 1F7 mAb, stimulated monocyte
TNF-α production (Figure 6a). This is consistent with
1F7 mAb causing early anti-inflammatory (alternative)
activation of unstimulated monocytes. As expected, the
monocytes developed homologous tolerance to LPS
challenge shown by declining production of TNF-α after
overnight LPS treatment (Figure 6a, NT+LPS versus
LPS+LPS treatment groups). Similar to the LPS-treated
Figure 4 Time-dependent effects of 1F7 mAb on IL-4 and IL-10 production by CD14+ monocytes and CD36+ lymphocytes. PBMC from
10 healthy donors were incubated with 1.92 μg/ml 1F7 mAb or IgMκ mAb control for 24, 48 and 72 h and surface stained with anti-CD36 or anti-
CD14. Cells were then fixed, permeabilized, incubated with anti-human IL-10, anti-IL-4 or isotype-matched controls and analyzed by flow
cytometry for intracellular IL-10 (a) and IL-4 (b). Gating for intracellular cytokine analysis was done as shown in Figure 3. Data shown represent
mean values ± SE.
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also developed tolerance to subsequent LPS challenge as
shown by a statistically significant decline in production
of TNF-α (Figure 6a, NT+LPS versus 1F7 mAb+LPS treat-
ment groups, p < 0.002).
Next, we studied how monocytes responded in terms of
IL-10 production to overnight LPS treatment (Figure 6b).
We found that 18 h incubation with 1F7 mAb, but notFigure 5 Impact of 1F7 mAb on TLR and NOD agonist-induced
IL-10 production by monocytes. Peripheral blood monocytes
obtained from 10 healthy donors were unstimulated (NT) or
stimulated with either 100 ng/ml LPS or 2.5 μg/ml PGN for 3 days in
the presence of 1.92 μg/ml 1F7 mAb or IgMκ control mAb.
Supernatant IL-10 concentration was then measured. All data shown
represent mean values ± SE and significant differences between 1F7
mAb-treated and IgMκ control mAb-treated monocytes are noted
(*p < 0.05).LPS induced monocyte IL-10 production (Figure 6b), con-
sistent with 1F7 mAb inducing early anti-inflammatory
(alternative) activation of monocytes. LPS-pretreated mono-
cytes produced a low, but detectable level of IL-10 following
repeated LPS stimulation (Figure 6b, p < 0.04). Overnight
culture of monocytes with either no treatment or with 1F7
mAb treatment prior to LPS restimulation resulted in a sig-
nificantly higher level of IL-10 compared to repeated LPS
treatments (Figure 6b, p < 0.04).
Discussion
Cytokine production profile is closely associated with
the outcome of viral infection. A predominance of pro-
inflammatory TH1-type cytokines such as IL-12 and
IFN-γ portends viral clearance or control, whereas dom-
inance of anti-inflammatory cytokines like IL-4 or IL-10
is more likely to herald chronic infection [12-15]. This
suggests that pathogens establishing chronic infection
have evolved mechanisms to skew host responses to-
wards cytokine profiles that favour their persistence. In a
number of infections, the level and timing of IL-10 pro-
duction is a pivotal factor in determining pathogen
clearance versus pathogen persistence [27-30]. We previ-
ously demonstrated an association between development
of chronic HCV infection, the level of anti-HCV anti-
bodies expressing a common idiotype recognized by the
1F7 mAb and expansion of B1 B cells expressing the same
idiotype [9]. Therefore, we speculated that HCV may ex-
ploit a link between B1 B cell activation, induction of 1F7
Figure 6 Influence of 1F7 mAb treatment on monocyte
endotoxin tolerance. Monocytes from 10 healthy donors were pre-
treated with 100 ng/ml LPS or 1.92 μg/ml 1F7 mAb for 18 h, washed
with LPS-free PBS and incubated for an additional 4 h with 1 μg/ml
LPS or 1.92 μg/ml 1F7 mAb. Levels of TNF-α (a) and IL-10 (b) in
supernatants were then measured. All data shown represent mean
values ± SE. Significant differences by repeated ANOVA measures are
noted between NT, LPS or 1F7 treatment (*p < 0.05) and between LPS
re-stimulated pairs (#p < 0.05).
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the immune system and establish chronic infection.
In this study, we found that the 1F7 mAb itself specif-
ically triggered IL-10 production by freshly-isolated
PBMC in a time and dose-dependent manner. Both
CD36+ lymphocytes and CD14+ monocytes produced
IL-10 in response to 1F7 mAb. Although the percentage
of CD36+ lymphocytes producing IL-10 doubled follow-
ing 1F7 mAb treatment, in absolute terms this was a
small number of responding cells compared to the num-
ber of monocytes producing IL-10 in response to 1F7
mAb treatment. Monocytes generally represent ~20% of
total PBMC, while CD36+ lymphocytes represent < 1%
of the lymphocyte population. Depletion of CD14+
monocytes reduced 1F7 mAb-stimulated IL-10 produc-
tion by > 80%, therefore, we concluded that CD36+lymphocytes are a minor source of IL-10 production fol-
lowing 1F7 mAb stimulation. The initial induction of
monocyte IL-10 production by 1F7 mAb was followed
by imposition of classical endotoxin tolerance in that the
pro-inflammatory response to TLR ligands such as LPS
was substantially blunted. If these in vitro responses to
the 1F7 mAb itself reflect responses that occur in vivo
following activation of B1 B cells bearing Ig with the 1F7
idiotype, this could represent a two-pronged approach
for pathogens to suppress immune responses that favour
clearance. Since the idiotype recognized by mAb 1F7 is
more common on CD5+ B1 B cells and these cells pro-
duce IL-10 [9-11], we initially felt that 1F7 interacting
in vitro with the Ig B cell receptor of B1 B cells might
mimic in vivo interactions with HCV proteins that dir-
ectly trigger IL-10 production. However, the major
source of IL-10 following exposure to 1F7 mAb is
monocytes, not B cells, indicating that the IL-10 is not
produced as a direct effect of 1F7 mAb binding to the Ig
B cell receptor of B1 B cells. While the mechanism by
which the 1F7 mAb itself stimulates monocyte produc-
tion of IL-10 in vitro is non-antigen specific, it may rep-
resent a mechanism by which HCV and other chronic
viral and bacterial pathogens selectively exploit idiotypic
connections to suppress immune responses. It was re-
cently shown that by differentially affecting TLR4 and
TLR8 pathways, IL-10 may selectively modulate mono-
cyte functions in persons with chronic HCV infection
[31]. This corroborates our data suggesting that IL-10
-mediated inhibition of the TLR4 signaling pathway in
monocytes induces endotoxin tolerance and favours al-
ternative activation of monocytes [31].
Convergent selection of anti-HCV antibodies bearing
the 1F7 idiotype occurs during HCV infection and in-
volves activation of B1 B cells [9]. Due to the high de-
gree of V region connectivity between B1 B cells, they
may be activated either by direct interaction with HCV
proteins or through interaction with other antibodies
simulated by HCV [32,33]. Since the 1F7 mAb is a
multimeric IgM mAb, its overall high avidity may pro-
duce exaggerated effects in vitro compared to IgG anti-
bodies. However, the high V region connectivity and
high frequency of expression of the 1F7 idiotype on B1
B cells suggests that immune complexes containing 1F7
Id-expressing and 1F7-like antibodies will form when B1
B cells are activated. If so, these complexes will have
similar overall avidity to the 1F7 IgM mAb. These com-
plexes or the 1F7-like antibodies themselves [8], should
act on circulating monocytes during acute HCV infec-
tion in the same way as the 1F7 mAb acts in vitro, by
inducing IL-10 production and endotoxin tolerance.
Suppression of proinflammatory cytokines such as
IFN-γ, and IL-12 by monocyte-derived IL-10 induced in
this manner would also favour chronic HCV infection.
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ing the 1F7 idiotype and B1 B cells with complementary
1F7 Id-like Ig receptors could underlie the association
we observed between high levels of antibodies express-
ing the 1F7 idiotype and chronic HCV infection [9].
Stimulation of 1F7 Id-expressing antibodies by chronic
pathogens susceptible to phagocytosis and intracellular
killing could favour their persistence through both the
direct IL-10 production and subsequent endotoxin toler-
ance imposed on monocytes.
The idea that pathogens can exploit idiotypic interac-
tions inherent to the humoral immune system was initially
proposed by Irun Cohen [34-36]. Common idiotypes arise
in the setting of chronic infection or chronic immune acti-
vation and are often carried on antibodies termed natural
antibodies [37]. Natural antibodies are produced by B1 B
cells and demonstrate cross-reactivity, autoreactivity and
high V region connectivity [38-40]. Activating immune re-
sponses along this axis of complementary autoreactive
and cross-reactive idiotypic dominance would in itself
benefit pathogens in that the response would be more
likely to remain diffuse. If activating immune responses
along this axis also leads to IL-10 production and mono-
cyte endotoxin tolerance, prospects for establishing
chronic infection would be further enhanced. In this re-
gard, all of the pathogens so far shown to stimulate anti-
bodies expressing the 1F7 idiotype either predominantly
(HCV) or uniformly (HIV and SIV) establish chronic in-
fection. This suggests that chronic pathogens have evolved
to exploit inherent immune system structural characteris-
tics such as high connectivity and functional coupling to
IL-10 induction, which are better suited to preserve self-
tolerance than to provide protection against pathogens.
Conclusions
Our previous study showed an association between 1F7
Id expression levels and chronic HCV infection [8]. In
the present study, we investigated the potential role of
antibodies bearing the 1F7 Id in modulating monocyte
cytokine responses. We observed that the mAb 1F7 itself
induced IL-10 production by unstimulated and TLR- or
NLR-agonist-stimulated monocytes and subsequently
imposed endotoxin tolerance on those monocytes. How-
ever, pretreatment of monocytes with LPS followed by
LPS was significantly different from pretreatment with
1F7 mAb followed by LPS in terms of both TNF-α pro-
duction and IL-10 production. This indicates that mono-
cyte endotoxin tolerance imposed by 1F7 mAb treatment
is incomplete compared to LPS-induced monocyte endo-
toxin tolerance. The 1F7 mAb probably provides a weaker
primary stimulus than LPS and acts through a different
signaling pathway. A distinct or divergent signaling path-
way from LPS is also suggested by the lack of significant
TNF-α production in response to 1F7 mAb. Although thereceptor on monocytes that mediates 1F7 mAb signaling
is unknown, the effects are selective and specific. Further
elucidation of the immunological and biochemical basis
for the association between 1F7 Id expression levels and
chronic HCV infection and for the selective action of 1F7
mAb on monocytes may aid in the design of novel thera-
peutic and prophylactic strategies against HCV and other
chronic pathogens.
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